Ending deaths from HIV-related cryptococcal meningitis by 2030

Amir Shroufi; Tom Chiller; Alex Jordan; David W Denning; Thomas S Harrison; Nelesh P Govender; Angela Loyse; Solange Baptiste; Radha Rajasingham; David R Boulware; Isabela Ribeiro; Joseph N Jarvis; Gilles Van Cutsem

doi:10.1016/S1473-3099(20)30909-9

Ending deaths from HIV-related cryptococcal meningitis by 2030

Lancet Infect Dis. 2021 Jan;21(1):16-18. doi: 10.1016/S1473-3099(20)30909-9. Epub 2020 Nov 30.

Authors

Affiliations

¹ CDC Foundation, Cape Town, South Africa. Electronic address: amir.shroufi@doctors.org.uk.
² Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
³ Manchester Fungal Infection Group, The University of Manchester, Manchester, UK; Global Action Fund for Fungal Infections, Geneva, Switzerland.
⁴ Centre for Global Health, Institute of Infection and Immunity, St George's University of London, London, UK; MRC Centre for Medical Mycology, University of Exeter, Exeter, UK; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
⁵ National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁶ Centre for Global Health, Institute of Infection and Immunity, St George's University of London, London, UK.
⁷ International Treatment Preparedness Coalition, Johannesburg, South Africa.
⁸ Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN, USA.
⁹ Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
¹⁰ Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; London School of Hygiene & Tropical Medicine, London, UK.
¹¹ Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; Southern Africa Medical Unit, Doctors Without Borders Southern Africa, Cape Town, South Africa.

No abstract available

MeSH terms

AIDS-Related Opportunistic Infections / drug therapy
AIDS-Related Opportunistic Infections / mortality*
AIDS-Related Opportunistic Infections / prevention & control*
Adult
Aged
Aged, 80 and over
Amphotericin B / therapeutic use
Antifungal Agents / therapeutic use
Female
Flucytosine / therapeutic use
Global Health
HIV Infections / complications*
HIV Infections / drug therapy
HIV Infections / mortality*
Humans
Male
Meningitis, Cryptococcal / drug therapy
Meningitis, Cryptococcal / etiology*
Meningitis, Cryptococcal / mortality*
Meningitis, Cryptococcal / prevention & control*
Middle Aged

Substances

Antifungal Agents
Amphotericin B
Flucytosine

MeSH terms

Substances

Grants and funding